Obuhangire bwa Allogene Therapeutics (ALLO) bwa Sikaati
Allogene Therapeutics
AI forecast: ALLO
AI ebandika ekiruho ky'obusobozi bw'omubere gw'ekiseera ekiddako, ekigero ky'omubere gw'ebirungi, n'ekigero ky'omubere gw'omwezi. Okuhinduka kuhakirizwa hakurikira obusobozi bwa nyuma. Bino ni obuhangire bw'obusobozi, si obuhangire bw'okuhanga.
Ebiharwa by'omwaka guhera mu myezi 6 eyita
Premium erikahyora ebyifujiraho by'AI eby'omutengo mu nsi y'omunzi omu, wiiki emu n'omwaka omu ku kizigirwa kino n'ebirala byonna.
Unlock Premium🔒 Ekihugho ky'obuhangire bw'obusobozi
Ekihugho ky'obuhangire bw'obusobozi — buli kihuugho ky'omubere gya nyuma hafi n'obusobozi bwa nyakuri — ni ekigero cya Premium.
Unlock PremiumEbikwata ku Kitongole Kino
Allogene Therapeutics, Inc. is a biotechnology company that develops T-cell therapies using allogeneic chimeric antigen receptors for the treatment of blood cancers and solid tumors. Allogene Therapeutics serves patients in California.
